Literature DB >> 24854990

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

V Visconte1, N Avishai2, R Mahfouz1, A Tabarroki1, J Cowen2, R Sharghi-Moshtaghin2, M Hitomi3, H J Rogers4, E Hasrouni1, J Phillips1, M A Sekeres5, A H Heuer2, Y Saunthararajah5, J Barnard6, R V Tiu5.   

Abstract

Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of the RNA splicing machinery are frequent in RARS/-T and defects of this gene were linked to RS formation. Here we showcase the differences in iron architecture of SF3B1-mutant and wild-type (WT) RARS/-T and provide new mechanistic insights by which SF3B1 mutations lead to differences in iron. We found higher iron levels in SF3B1 mutant vs WT RARS/-T by transmission electron microscopy/spectroscopy/flow cytometry. SF3B1 mutations led to increased iron without changing the valence as shown by the presence of Fe(2+) in mutant and WT. Reactive oxygen species and DNA damage were not increased in SF3B1-mutant patients. RNA-sequencing and Reverse transcriptase PCR showed higher expression of a specific isoform of SLC25A37 in SF3B1-mutant patients, a crucial importer of Fe(2+) into the mitochondria. Our studies suggest that SF3B1 mutations contribute to cellular iron overload in RARS/-T by deregulating SLC25A37.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24854990     DOI: 10.1038/leu.2014.170

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Chronic refractory anemia with sideroblastic bone marrow; a study of four cases.

Authors:  S E BJORKMAN
Journal:  Blood       Date:  1956-03       Impact factor: 22.113

2.  Detection and evaluation of intron retention events in the human transcriptome.

Authors:  Pedro Alexandre Favoretto Galante; Noboru Jo Sakabe; Natanja Kirschbaum-Slager; Sandro José de Souza
Journal:  RNA       Date:  2004-05       Impact factor: 4.942

3.  Mapping and quantifying mammalian transcriptomes by RNA-Seq.

Authors:  Ali Mortazavi; Brian A Williams; Kenneth McCue; Lorian Schaeffer; Barbara Wold
Journal:  Nat Methods       Date:  2008-05-30       Impact factor: 28.547

4.  Frataxin, a molecule of mystery: trading stability for function in its iron-binding site.

Authors:  Darius J R Lane; Des R Richardson
Journal:  Biochem J       Date:  2010-02-09       Impact factor: 3.857

5.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

6.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Authors:  Valeria Visconte; Heesun J Rogers; Jarnail Singh; John Barnard; Manoj Bupathi; Fabiola Traina; James McMahon; Hideki Makishima; Hadrian Szpurka; Anna Jankowska; Andres Jerez; Mikkael A Sekeres; Yogen Saunthararajah; Anjali S Advani; Edward Copelan; Haruhiko Koseki; Kyoichi Isono; Richard A Padgett; Sami Osman; Kazunori Koide; Christine O'Keefe; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

Review 7.  Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.

Authors:  V Visconte; H Makishima; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2012-05-15       Impact factor: 11.528

8.  Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Authors:  F Traina; V Visconte; P Elson; A Tabarroki; A M Jankowska; E Hasrouni; Y Sugimoto; H Szpurka; H Makishima; C L O'Keefe; M A Sekeres; A S Advani; M Kalaycio; E A Copelan; Y Saunthararajah; S T Olalla Saad; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

9.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Authors:  Andrea Pellagatti; Mario Cazzola; Aristoteles A N Giagounidis; Luca Malcovati; Matteo G Della Porta; Sally Killick; Lisa J Campbell; Li Wang; Cordelia F Langford; Carrie Fidler; David Oscier; Carlo Aul; James S Wainscoat; Jacqueline Boultwood
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

10.  The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload.

Authors:  Clara Camaschella; Alessandro Campanella; Luigia De Falco; Loredana Boschetto; Roberta Merlini; Laura Silvestri; Sonia Levi; Achille Iolascon
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

View more
  23 in total

Review 1.  Therapeutic targeting of splicing in cancer.

Authors:  Stanley Chun-Wei Lee; Omar Abdel-Wahab
Journal:  Nat Med       Date:  2016-09-07       Impact factor: 53.440

Review 2.  Spliceosomal factor mutations and mis-splicing in MDS.

Authors:  Courtney E Hershberger; Noah J Daniels; Richard A Padgett
Journal:  Best Pract Res Clin Haematol       Date:  2020-08-01       Impact factor: 3.020

Review 3.  Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.

Authors:  Akihide Yoshimi; Omar Abdel-Wahab
Journal:  Int J Hematol       Date:  2017-05-02       Impact factor: 2.490

Review 4.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

Review 5.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

Review 6.  Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy.

Authors:  Maayan Salton; Tom Misteli
Journal:  Trends Mol Med       Date:  2015-12-14       Impact factor: 11.951

7.  Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Authors:  Andrea Pellagatti; Richard N Armstrong; Violetta Steeples; Eshita Sharma; Emmanouela Repapi; Shalini Singh; Andrea Sanchi; Aleksandar Radujkovic; Patrick Horn; Hamid Dolatshad; Swagata Roy; John Broxholme; Helen Lockstone; Stephen Taylor; Aristoteles Giagounidis; Paresh Vyas; Anna Schuh; Angela Hamblin; Elli Papaemmanuil; Sally Killick; Luca Malcovati; Marco L Hennrich; Anne-Claude Gavin; Anthony D Ho; Thomas Luft; Eva Hellström-Lindberg; Mario Cazzola; Christopher W J Smith; Stephen Smith; Jacqueline Boultwood
Journal:  Blood       Date:  2018-06-21       Impact factor: 22.113

8.  FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity.

Authors:  Yvette Y Yien; Jiahai Shi; Caiyong Chen; Jesmine T M Cheung; Anthony S Grillo; Rishna Shrestha; Liangtao Li; Xuedi Zhang; Martin D Kafina; Paul D Kingsley; Matthew J King; Julien Ablain; Hojun Li; Leonard I Zon; James Palis; Martin D Burke; Daniel E Bauer; Stuart H Orkin; Carla M Koehler; John D Phillips; Jerry Kaplan; Diane M Ward; Harvey F Lodish; Barry H Paw
Journal:  J Biol Chem       Date:  2018-10-26       Impact factor: 5.157

Review 9.  Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.

Authors:  Valeria Visconte; Ramon V Tiu; Heesun J Rogers
Journal:  Blood Res       Date:  2014-12-23

10.  Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Authors:  H Dolatshad; A Pellagatti; M Fernandez-Mercado; B H Yip; L Malcovati; M Attwood; B Przychodzen; N Sahgal; A A Kanapin; H Lockstone; L Scifo; P Vandenberghe; E Papaemmanuil; C W J Smith; P J Campbell; S Ogawa; J P Maciejewski; M Cazzola; K I Savage; J Boultwood
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.